AGK 102
Alternative Names: AGK-102Latest Information Update: 29 Feb 2024
At a glance
- Originator Korea Atomic Energy Research Institute
- Developer Algok Bio; Korea Atomic Energy Research Institute
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action TM4SF4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer; Lung cancer; Pancreatic cancer
Most Recent Events
- 19 Feb 2024 Preclinical trials in Cancer in USA (Parenteral) (Algok Bio pipeline, February 2024)
- 19 Feb 2024 Preclinical trials in Liver cancer in South Korea (Parenteral) (Algok Bio pipeline, February 2024)
- 19 Feb 2024 Preclinical trials in Liver cancer in USA (Parenteral) (Algok Bio pipeline, February 2024)